In vivo assessment of pharmacokinetic interactions of empagliflozin and henagliflozin with sorafenib: an animal-based study

Background Sorafenib is a multi-targeted tyrosine kinase inhibitor (TKI) used for the treatment of advanced renal cell carcinoma, hepatocellular carcinoma (HCC), and radioactive iodine-resistant thyroid carcinoma. Notably, glucose transporters sodium-glucose cotransporter 2 (SGLT2) and glucose trans...

Full description

Saved in:
Bibliographic Details
Main Authors: Wenyu Du, Zihan Liu, Zhi Wang, Xin Zhou, Zhanjun Dong, Ying Li
Format: Article
Language:English
Published: PeerJ Inc. 2025-07-01
Series:PeerJ
Subjects:
Online Access:https://peerj.com/articles/19662.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!